SCHEMBL3882941

SCHEMBL3882941

COC(=O)c1cc(Br)c(C#N)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.41
KDM4E B2RXH2 7/20 0.40
HPGD P15428 6/20 0.40
ALDH1A1 P00352 5/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CSNK2A2 P19784 1/20 0.39
KDR P35968 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
ATM Q13315 2/20 0.39
HSD17B10 Q99714 2/20 0.39
OPRD1 P41143 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 2/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23531570 0.81 KDM4E (0.39) KDM4EHPGDALDH1A1MAPK1SMN1; SMN2
SCHEMBL3882730 0.81 KDM4E (0.42) KDM4EHPGDALDH1A1MAPK1SMN1; SMN2
SCHEMBL1529974 0.78 GSK3B (0.53) PTPN2KDM4EHPGDALDH1A1MAPK1
SCHEMBL1529472 0.77 CSNK2A2 (0.45) PTPN2KDM4EHPGDALDH1A1MAPK1
SCHEMBL3890611 0.76 USP10 (0.44) KDM4EHPGDALDH1A1SMN1; SMN2KDR
SCHEMBL19436395 0.76 CSNK2A2 (0.42) KDM4EHPGDALDH1A1MAPK1SMN1; SMN2
SCHEMBL1529851 0.75 DAO (0.43) PTPN2KDM4EHPGDALDH1A1MAPK1
SCHEMBL1530025 0.75 OPRD1 (0.43) PTPN2KDM4EHPGDALDH1A1MAPK1
SCHEMBL1530007 0.75 PTPN2 (0.43) PTPN2KDM4EHPGDALDH1A1MAPK1
SCHEMBL20876195 0.75 KDM4E (0.43) KDM4EHPGDALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
US-20160289196-A1 PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-06 US disclosed
US-7485661-B2 Heterobicyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-02-03 US disclosed
EP-1534716-B1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-04-23 EP disclosed
US-20060160874-A1 Heterobicyclic pyrazole derivatives as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2006-07-20 US disclosed
EP-1534716-A1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2005-06-01 EP disclosed
WO-2004007504-A1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160874-A1 Heterobicyclic pyrazole derivatives as kinase inhibitors MAP2K2, MAP3K15, MAP3K5 PTPN2 1030/4885KDM4E 1936/4885HPGD 1816/4885
US-20160289196-A1 PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TNIK, TNNI3K, TNK1 PTPN2 403/4885KDM4E 1268/4885HPGD 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.